

# Laura Torrens

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3980371/publications.pdf>

Version: 2024-02-01

7  
papers

522  
citations

1307594

7  
h-index

1720034

7  
g-index

7  
all docs

7  
docs citations

7  
times ranked

675  
citing authors

#	ARTICLE	IF	CITATIONS
1	Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. <i>Gut</i> , 2023, 72, 129-140.	12.1	90
2	Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 2449-2460.	7.0	39
3	Liver Injury Increases the Incidence of HCC following AAV Gene Therapy in Mice. <i>Molecular Therapy</i> , 2021, 29, 680-690.	8.2	61
4	Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma. <i>Hepatology</i> , 2021, 74, 2652-2669.	7.3	95
5	Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 6350-6361.	7.0	35
6	Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications. <i>Journal of Hepatology</i> , 2020, 73, 328-341.	3.7	82
7	Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity. <i>Journal of Hepatology</i> , 2017, 66, 952-961.	3.7	120